Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 14/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5969755 | 0.87 | AR (0.43) | ARCYP11B1CYP11B2TRPV4 | |
| SCHEMBL24495511 | 0.83 | AR (0.45) | ARCYP11B1CYP11B2TRPV4 | |
| SCHEMBL1365376 | 0.80 | AR (0.46) | ARHTR2AHTR2CHTR2BCYP11B1 | |
| SCHEMBL2693449 | 0.80 | AR (0.47) | ARCYP11B1CYP11B2TRPV4 | |
| SCHEMBL3333071 | 0.78 | CYP11B2 (0.42) | ARHTR2AHTR2CHTR2BCYP11B1 | |
| SCHEMBL223893 | 0.78 | AR (0.42) | ARCYP11B1CYP11B2TRPV4 | |
| SCHEMBL6364089 | 0.78 | TRPV4 (0.42) | ARCYP11B1CYP11B2TRPV4 | |
| SCHEMBL29863815 | 0.78 | AR (0.51) | AR | |
| SCHEMBL3976812 | 0.78 | AR (0.51) | ARTRPV4 | |
| SCHEMBL13106347 | 0.78 | AR (0.51) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070277-A | Androgen receptor PROTAC | 葛兰素史密斯克莱知识产权发展有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12577231-B2 | Androgen receptor PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| EP-4593824-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250129070-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025081082-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025061906-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-27 | — | — | WO | disclosed |
| US-20250100981-A1 | Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4 | BOEHRINGER INGELHEIM INT (DE) | 2025-03-27 | — | — | US | disclosed |
| WO-2025027049-A1 | (2S,5R)-5-(HYDROXYMETHYL)MORPHOLINE-2-CARBOXAMIDES AS AGONISTS OF SSTR4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2006076317-A9 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ACADIA PHARM INC (US) | 2007-09-27 | — | — | WO | disclosed |
| EP-1836202-A2 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | Acadia Pharmaceuticals Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2007092400-A1 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2006124447-A2 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060264463-A1 | Chemical compounds | MEDTECH CONVERGENCE FUND, L.P. | 2006-11-23 | — | — | US | disclosed |
| US-20060173037-A1 | Aminophenyl derivatives as selective androgen receptor modulators | ACADIA PHARMACEUTICALS INC. | 2006-08-03 | — | — | US | disclosed |
| WO-2006076317-A2 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060160845-A1 | Aminophenyl derivatives as selective androgen receptor modulators | ACADIA PHARMACEUTICALS INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1625114-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004099144-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264463-A1 | Chemical compounds | CCR3, CCR1, CCR4 | AR 2692/4885HTR2A 3177/4885HTR2C 1725/4885 |
| US-20060173037-A1 | Aminophenyl derivatives as selective androgen receptor modulators | AR, NR5A1, ESRRA | AR 1/4885HTR2A 224/4885HTR2C 179/4885 |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR5A2, NR3C1 | AR 5/4885HTR2A 2824/4885HTR2C 2211/4885 |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | AR, CRBN, PSMA3 | AR 1/4885HTR2A 2816/4885HTR2C 1030/4885 |
| US-12577231-B2 | Androgen receptor PROTACS | AR, CRBN, PSMA3 | AR 1/4885HTR2A 2816/4885HTR2C 1030/4885 |
| US-20250100981-A1 | Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4 | SSTR4, SSTR5, SSTR2 | AR 428/4885HTR2A 70/4885HTR2C 44/4885 |
| US-20060160845-A1 | Aminophenyl derivatives as selective androgen receptor modulators | AR, NR5A1, ESRRA | AR 1/4885HTR2A 224/4885HTR2C 179/4885 |
| US-20250129070-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | AR, SHBG, FSHR | AR 1/4885HTR2A 662/4885HTR2C 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.